LY3200882 + itraconazole

LY3200882 + itraconazole is a combination of two small molecule drugs: LY3200882, a next-generation, selective transforming growth factor beta receptor 1 (TGFβR1/ALK5) inhibitor, and itraconazole, an established antifungal agent. LY3200882 acts as an ATP-competitive inhibitor of the serine-threonine kinase domain of TGFβR1, blocking TGFβ-mediated signaling pathways involved in tumor growth, metastasis, and immune evasion. It was developed to be more potent and selective than previous inhibitors and has demonstrated antitumor activity and immunomodulatory effects in preclinical and early clinical studies in advanced cancers, particularly in monotherapy and in combination with chemotherapy regimens[1][2][3]. Itraconazole is classically used as an antifungal, functioning as an inhibitor of ergosterol synthesis by blocking the fungal enzyme lanosterol 14α-demethylase, but has also been studied for potential anticancer properties through inhibition of Hedgehog signaling and angiogenesis. This specific combination (LY3200882 + itraconazole) is not documented in major clinical trials or literature as a unique investigational product, but both drugs individually have established pharmacological profiles and routes of administration.